KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Operating Leases: 2020-2024

Historic Operating Leases for Adaptive Biotechnologies (ADPT) over the last 5 years, with Dec 2024 value amounting to $79.1 million.

  • Adaptive Biotechnologies' Operating Leases fell 11.54% to $72.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.4 million, marking a year-over-year decrease of 11.54%. This contributed to the annual value of $79.1 million for FY2024, which is 11.46% down from last year.
  • According to the latest figures from FY2024, Adaptive Biotechnologies' Operating Leases is $79.1 million, which was down 11.46% from $89.4 million recorded in FY2023.
  • Over the past 5 years, Adaptive Biotechnologies' Operating Leases peaked at $106.7 million during FY2021, and registered a low of $79.1 million during FY2024.
  • Over the past 3 years, Adaptive Biotechnologies' median Operating Leases value was $89.4 million (recorded in 2023), while the average stood at $89.1 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' Operating Leases grew by 2.25% in 2021 and then declined by 11.46% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' Operating Leases (Yearly) stood at $104.3 million in 2020, then grew by 2.25% to $106.7 million in 2021, then dropped by 7.42% to $98.8 million in 2022, then declined by 9.50% to $89.4 million in 2023, then declined by 11.46% to $79.1 million in 2024.